Johnson Fistel, PLLP is investigating VenHub Global, Inc. following its 2025 annual report revealing a $62.4 million net loss, low revenue of $864,450, and serious financial distress including a $10.3 million stockholders' deficit. The company warned it might cease operations without additional capital. The investigation focuses on whether VenHub misled investors or withheld important information. Investors who suffered losses are encouraged to contact the law firm for potential recovery under securities laws.
Johnson Fistel's investigation of VenHub Global, Inc. is presented here alongside Pluang's Technology sector market data for context. For readers following the Technology sector, as of Sep 16, 2026 00:11 WIB, out of 150 US tech stocks tradable on Pluang, 68 rose and 82 fell. Notable price changes include FUBO at USD 11.24 with a -5.31% change, STX at USD 763.38 down -5.28%, and CLSK at USD 12.58 down -5.20%.
Uber Technologies reported a 25% year-over-year increase in gross bookings to $53.7 billion in Q1 2026, driven by growth in ride-hailing, delivery, grocery, retail, and membership services. CEO Dara Khosrowshahi's recent purchase of 141,000 shares wo...
Waystar Holding Corp, a healthcare software company valued at around $5.1 billion, saw its stock rise 8.6% to $27.05 following reports that it is evaluating strategic options, including a potential sale. Barclays set a new price target of $30, sugges...
MasterCraft Boat Holdings reported fiscal Q4 2026 adjusted earnings of $0.67 per share and revenue of $129.94 million, surpassing estimates. Revenue growth was driven by its Performance and Wake business and the Marine Products acquisition, which add...
Redwood Trust's CFO, Carillo Brooke, increased her stake by purchasing 26,065 shares, showing confidence despite a major shareholder urging the board to consider selling the company. The stock trades at a 33% discount to its GAAP book value due to ri...
BioMarin Pharmaceutical received a price target upgrade to $97 from BMO Capital, reflecting about 50% upside from current levels. This follows positive Phase 3 trial results for VOXZOGO®, a treatment for hypochondroplasia, showing significant growth ...
